Spermosens AB (STU:9R5) Debt-to-Equity : 0.03 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Spermosens AB Debt-to-Equity?

Spermosens AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.05 Mil. Spermosens AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.00 Mil. Spermosens AB's Total Stockholders Equity for the quarter that ended in Sep. 2024 was €1.94 Mil. Spermosens AB's debt to equity for the quarter that ended in Sep. 2024 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Spermosens AB's Debt-to-Equity or its related term are showing as below:

STU:9R5' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.04 Max: 1.61
Current: 0.03

During the past 5 years, the highest Debt-to-Equity Ratio of Spermosens AB was 1.61. The lowest was 0.02. And the median was 0.04.

STU:9R5's Debt-to-Equity is ranked better than
88.54% of 192 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.275 vs STU:9R5: 0.03

Spermosens AB Debt-to-Equity Historical Data

The historical data trend for Spermosens AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spermosens AB Debt-to-Equity Chart

Spermosens AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

1.61

0.02

0.23

0.75

Spermosens AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial													0.25	0.75	1.06	0.03	0.03

Competitive Comparison of Spermosens AB's Debt-to-Equity

For the Diagnostics & Research subindustry, Spermosens AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spermosens AB's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Spermosens AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Spermosens AB's Debt-to-Equity falls into.

Spermosens AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Spermosens AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.83	+	0.021)	/	1.135
	=	0.75

Spermosens AB's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.052	+	0.003)	/	1.935
	=	0.03

Spermosens AB (STU:9R5) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Spermosens AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Spermosens AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Spermosens AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Spermosens AB (STU:9R5) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

SPERM:Sweden

Address

Scheeletorget 1, Medicon Village, Lund, SWE, 223 81

Website

https://www.spermosens.com

Spermosens AB is developing a revolutionary platform technology for diagnosing male-factor infertility and directing to the right infertility treatment. It is a developer of medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments.

Spermosens AB Headlines

No Headlines